Cancer nanotherapeutic - Ovensa
Alternative Names: siRNA Gal-1; TRIOZAN™/siRNA Gal-1Latest Information Update: 15 Jan 2024
At a glance
- Originator Ovensa
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Galectin 1 inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Head and neck cancer
Most Recent Events
- 10 Oct 2023 Early research in Head and neck cancer in Canada (unspecified route)